Modulation of the discriminative stimulus effects of mu opioid agonists in rats: I. Effects of dopamine D2/3 antagonists.
Mu opioid receptor agonists such as morphine stimulate the release of dopamine (DA) in various brain regions. These increases in DA are thought to be involved in some of the behavioral effects of mu agonists. The present study was designed to examine the modulatory actions of two D2/3 antagonists (nafadotride and eticlopride), the D2/3 partial agonist BP897, the D1/2 antagonist flupenthixol, and the D1 antagonist SCH23390 on the discriminative stimulus effects of the mu partial agonist nalbuphine and the higher-efficacy mu agonists heroin, methadone and morphine, in rats trained to discriminate heroin from water. Both nafadotride and eticlopride attenuated the effects of the mu agonists, whereas BP897 was effective against nalbuphine and partially effective against morphine. Flupenthixol attenuated the heroin-like discriminative stimulus effects of heroin and morphine, although not as completely as nafadotride or eticlopride. SCH23390 was least effective and produced little attenuation. These results demonstrate that the discriminative stimulus effects of mu agonists in rats are more readily attenuated by drugs that block D2-like, rather than D1-like, receptors.
Cook
C D
CD
Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia 23298-0613, USA. ccook@hsc.vcu.edu
Beardsley
P M
PM
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D001921:Brain / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism*; D018492:Dopamine Antagonists / Q000494:pharmacology*; D065127:Dopamine D2 Receptor Antagonists; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005475:Flupenthixol / Q000494:pharmacology; D003932:Heroin / Q000494:pharmacology; D008691:Methadone / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology; D009042:Motivation; D009266:Nalbuphine / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D010879:Piperazines / Q000494:pharmacology; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D020318:Rats, Long-Evans; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors; D050637:Receptors, Dopamine D3; D017450:Receptors, Opioid, mu / Q000819:agonists*; D012457:Salicylamides / Q000494:pharmacology
D001552:Benzazepines; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; C493595:Drd3 protein, rat; D009281:Naphthalenes; D010879:Piperazines; D011759:Pyrrolidines; D017447:Receptors, Dopamine D1; D050637:Receptors, Dopamine D3; D017450:Receptors, Opioid, mu; D012457:Salicylamides; C120565:BP 897; D003932:Heroin; D009020:Morphine; D005475:Flupenthixol; C045989:eticlopride; C097285:nafadotride; D009266:Nalbuphine; D008691:Methadone; D004298:Dopamine